Ukusebenza Okuphezulu Kokwelashwa Kwe-CD7 CAR-T Kwezifo Ezingama-B-Cell: Intuthuko Ekwelapheni Umdlavuza
Ucwaningo lwakamuva luqokomisa ukusebenza kahle nokuphepha kokwelashwa kwamaseli e-CD7 CAR-T ekwelapheni i-B-cell acute lymphoblastic leukemia (B-ALL) ephinde yabuya noma engaphikisi kanye ne-T-cell lymphoblastic lymphoma (T-LBL). Lolu cwaningo lwenziwa yi-BIOOCUS ngokubambisana ne-Lu Daopei Hospital, lubonisa imiphumela ethembisayo ezigulini, lunikeza enye indlela enamandla esikhundleni se-chemotherapy evamile.
Kuthuthuko olujabulisayo lwe Ukwelashwa Komdlavuza, I-BIOOCUS, ngokubambisana neLu Daopei Hospital, iveze ucwaningo oluqavile mayelana nokusetshenziswa kokwelashwa kwe-CD7 chimeric antigen receptor (CAR) T-cell. Le ndlela entsha, ehlose i-B-cell acute lymphoblastic leukemia (B-ALL) ephinde yabuyiselwa noma engaphikisi kanye ne-T-cell lymphoblastic lymphoma (T-LBL), ikhombisa ukusebenza kahle nokuphepha okuphezulu, ithuthukisa kakhulu imiphumela yeziguli.
Ucwaningo, olwanyatheliswa ephephabhukwini elidumile, luhilele ukuqhathaniswa okufanayo kweziguli ezithola ukwelashwa kwe-CD7 CAR-T okulandelwe ukuhlanganiswa nokufakelwa kwe-allogeneic hematopoietic stem cell (allo-HSCT) kulabo abaphathwa nge-chemotherapy ngaphambi kokufakelwa. Okutholakele ocwaningweni kubonisa ukuthi iziguli ezithole ukuxolelwa okuphelele (CR) ngokwelashwa kwe-CD7 CAR-T zinemiphumela efanayo yokusinda isikhathi eside nalabo abaphathwa nge-chemotherapy evamile. Okubalulekile ukuthi ucwaningo alutholanga ukwanda okukhulu kwezinkinga zangemuva kokufakelwa, njengesifo se-graft-versus-host (GVHD), ukutheleleka, noma ezinye izehlakalo ezimbi.
Izinto ezibalulekile ocwaningweni zifaka:
- Izinga Lokuxolelwa Eliphelele: Ukwelashwa kwe-CD7 CAR-T kubonise izinga lokuhlehla okuphelele okumangalisayo, njengoba iziguli ezingaphezu kuka-97% zisabela kahle ekwelashweni.
- Iphrofayili Yokuphepha: Naphezu kwendlela entsha yokusebenzisa ukwelashwa kwe-CAR-T, ukwelashwa kwabekezelelwa kahle, kunemiphumela emibi emincane futhi akukho ukwanda okukhulu kwe-GVHD yezinga eliphezulu noma ezinye izinkinga ezinkulu.
- Impumelelo Ngemva Kokufakelwa: Iziguli ezithola ukwelashwa kwe-allo-HSCT ngemuva kokuthola i-CR nge-CD7 CAR-T therapy zathola ukusinda okuhle kwe-overall survival (OS) kanye nokusinda okungenalo i-leukemia (LFS), okuqhathaniswa nokwelashwa kwendabuko okusekelwe ku-chemotherapy.
Lolu cwaningo luyingqophamlando ebalulekile emkhakheni we- Ukwelashwa Ngezifo Zomdlavuza, okunikeza ithemba ezigulini ezinezinhlobo ze-leukemia kanye ne-lymphoma eziphinde zabuyela emuva noma ezingalapheki. I-BIOOCUS isalokhu izibophezele ekuthuthukiseni imingcele yokwelashwa kwe-CAR-T, ihlinzeka ngezixazululo ezintsha ezigulini eseziqede izinketho zokwelapha ezivamile. Njengoba umhlaba wamukela lezi zindlela zokwelapha ezisezingeni eliphezulu, i-BIOOCUS ihamba phambili ekuthuthukiseni ukwelashwa okuletha ushintsho lwangempela emiphumeleni yeziguli.